NIT
TVRD

NumerixS Investment Technologies’s Tvardi Therapeutics TVRD Stock Holding History

NumerixS Investment Technologies’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-25
Closed -$14K – 1322
2019
Q4 		$14K Buy
+25
New +$17.5K ﹤0.01% 966
2019
Q1 		– Sell
-264
Closed -$121K – 1378
2018
Q4 		$121K Buy
+264
New +$170K 0.04% 505
2017
Q1 		– Sell
-11
Closed -$4K – 1419
2016
Q4 		$4K Buy
+11
New +$3.53K ﹤0.01% 1079

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NumerixS Investment Technologies's TVRD Position: Q1 2020 in Review

NumerixS Investment Technologies sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 25 shares — an estimated $14K sold.

NumerixS Investment Technologies first reported a position in TVRD in Q4 2016 and held it in 3 quarters. The position peaked at $121K in Q4 2018. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

  • NumerixS Investment Technologies reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 25 Tvardi Therapeutics shares in Q1 2020, an estimated $14K.
  • NumerixS Investment Technologies first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 3 quarters.
  • NumerixS Investment Technologies's Tvardi Therapeutics position peaked at $121K in Q4 2018.
  • 133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on NumerixS Investment Technologies's 13F filing for Q1 2020, filed 15 May 2020.